The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia

Bernhard Moser, Sophie Edtmayer, Agnieszka Witalisz-Siepracka and Dagmar Stoiber*

Abstract: Aberrant Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling is implicated in the pathogenesis of acute myeloid leukemia (AML), a highly heterogeneous hematopoietic malignancy. The management of AML is complex and despite impressive efforts into better understanding its underlying molecular mechanisms, survival rates in the elderly have not shown a substantial improvement over the past decades. This is particularly due to the heterogeneity of AML and the need for personalized approaches. Due to the crucial role of the deregulated JAK-STAT signaling in AML, selective targeting of the JAK-STAT pathway, particularly constitutively activated STAT3 and STAT5 and their associated upstream JAKs, is of great interest. This strategy has shown promising results in vitro and in vivo with several compounds having reached clinical trials. Here, we summarize recent FDA approvals and current potential clinically relevant inhibitors for AML patients targeting JAK and STAT proteins. This review underlines the need for detailed cytogenetic analysis and additional assessment of JAK-STAT pathway activation. It highlights the ongoing development of new JAK-STAT inhibitors with better disease specificity, which opens up new avenues for improved disease management.

Keywords: STAT; JAK; acute myeloid leukemia; AML; tyrosine kinase inhibitor; FLT3

1. Introduction

Acute myeloid leukemia (AML) is a heterogeneous malignant disorder characterized by abnormal proliferation and differentiation of hematopoietic stem and progenitor cells (HSPCs). This clonal expansion leads to an accumulation of immature myeloid precursors in the hematopoietic tissue and peripheral blood, which occurs at the expense of normal hematopoiesis and results in anemia, leukopenia or thrombocytopenia [1,2]. The global AML burden increases with the ageing population, because the incidence of AML increases with age and is predominantly diagnosed in older patients with a median age at diagnosis of 68 years [3]. The American Cancer Society estimated that AML will be responsible for 11,400 deaths in the United States in 2021, accounting for the highest percentage (48%) of leukemic deaths, with a rate of relative 5-year survival (2010–2016) of 68% (age < 20) and 8.2% in patients aged 65 years and over [4]. The development of intensive consolidation chemotherapy programs and progress in supportive care have ameliorated the survival rate of younger adults with AML (aged < 60 years); however, the survival rate in the elderly has failed to show a substantial improvement over the past decades [5,6]. The characterization of distinct AML subtypes by multiple cytogenetic and molecular abnormalities is used to better predict the prognosis of patients and to make treatment decisions under refined risk stratification. Recent advances in next-generation sequencing technology play a major role and provide an in-depth insight into the mutational driver landscape of AML, which will continue to become increasingly important in assessing the risk of AML progression. Identification of new unique biomarkers associated with acute leukemias significantly improves the prognosis and diagnosis of genetically unique AML patients and improves...
the diagnostic criteria [7–10]. The current World Health Organization (WHO) classification considers morphologic, cytogenetic and molecular genetic analysis, clinical history, and prognostic and immunophenotypic data. It defines specific disease entities by focusing on genetic subgroups: AML with recurrent genetic abnormalities (AML-RGA), AML with myelodysplasia-related changes (MDS-AML), therapy-related AML (tAML) and AML not otherwise specified (AML-NOS) [11]. Analysis of the Surveillance, Epidemiology, and End Results (SEER) database, containing 32,941 AML patients, showed that AML patients who were not diagnosed according to WHO classification lived shorter than patients diagnosed using WHO-type classification [12]. This clearly reflects that many AML patients may not receive an optimal treatment and underpins the benefits of targeted AML therapy. Each patient’s AML is genetically unique, since individual leukemias can result from distinct mutations with even more diverse subclones. More than 86% of AML patients harbor two or more driver mutations, while only 3% do not contain any known driver mutation [13]. Most frequent alterations appear in genes expressing signaling proteins (e.g., KIT, FLT3, NPM1, CEBPA), epigenetic modulators (e.g., EXH2, TET2, DNMT3A) or as chromosomal rearrangements that generate fusion transcripts of genes encoding for transcription factors. These include, for example, RUNXI-RUNXIT1, PML-RARA or MLLT3-MLL [14–21].

The Janus kinase (JAK) family of nonreceptor tyrosine kinases comprises pivotal mediators of growth factor and cytokine signaling, activating i.a. downstream signal transducer and activator of transcription (STAT) factors [22–24]. STATs, particularly STAT3 and STAT5, are hyperactivated in various solid tumors and hematological malignancies stimulating cellular proliferation and survival [25–31]. STAT3 and STAT5 are constitutively activated in 44–76% of AML patients [32–34] and individuals show a shorter disease-free survival with constitutive STAT3 activity than without [33]. Interestingly, our group demonstrated that the alternatively spliced STAT3β isoform has a tumor-suppressive role and that the STAT3β/α mRNA expression ratio positively correlates with overall survival, representing a promising prognostic marker in AML patients [35]. Despite significant advances, the exact contribution of JAKs and STATs to the development of AML remains to be discovered. Current trends in ongoing research are reflected in the approaching progress of drug development and their recent approvals. As a consequence, especially for STAT3 and STAT5, the upstream JAKs and co-factors have become attractive therapeutic targets in AML. Here, we present a comprehensive overview of clinically relevant inhibitors for AML patients, acting on JAK-STAT signaling.

2. JAK-STAT Signaling
2.1. The JAK-STAT Signaling Pathway

In mammals, four JAK proteins (JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2)) and seven STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6) have been identified. The binding of a ligand to its receptor is a critical step in precisely determining the context-dependent effect of downstream signaling by distinct JAK-STAT combinations with a high degree of specificity. The JAK-STAT signaling pathway links the receptor binding of extracellular ligands like cytokines, hormones and growth factors via a ubiquitous intracellular signaling cascade with the transcriptional machinery in the nucleus. It is tightly regulated under physiological conditions coordinating a wide range of fundamental biological mechanisms, including cell proliferation, differentiation, apoptosis and inflammation. Dysregulation has been identified in severe pathological circumstances and is commonly associated with constitutively active STATs promoting, among others, intense inflammatory conditions or tumorigenesis [36].

The highly conserved JAKs, JAK1, JAK2 and TYK2, are ubiquitously expressed, whereas JAK3 is predominantly expressed in hematopoietic cells, in particular lymphoid and myeloid cells [37]. Among tyrosine kinases, JAKs are unique for their non-covalent interaction via N-terminal 4.1, ezrin, radixin, moesin (FERM) and Src Homology 2 (SH2) domains with class I and II cytokine receptors [38]. The C-terminal region contains the active tyrosine kinase and the pseudokinase domain, which regulates both basal and cytokine-
induced activation [39,40]. Mechanistically, the JAK-STAT signaling pathway (Figure 1) is activated by ligand binding to their cognate multimeric transmembrane receptors (such as interleukin (IL), interferon (IFN) and hormone receptors) leading to conformational changes of the receptor. Receptor-associated JAKs are now in close proximity, inducing their activation by autophosphorylation and/or transphosphorylation and subsequently the phosphorylation of the receptor-associated tyrosine residues. This in turn provides a docking site for the SH2 domain of STAT proteins and leads to their JAK-mediated phosphorylation of a conserved C-terminal tyrosine residue. Subsequently the phosphorylated tyrosine of one receptor-associated STAT reciprocally binds the SH2 domain of another receptor-associated STAT [36,41]. This anti-parallel to parallel homo- or heterodimerization of phosphorylated STAT (pSTAT) proteins ensures the release from the receptor and the translocation into the nucleus by importins. STAT2, STAT3, STAT5, and STAT6 translocate constantly to the nucleus independent of tyrosine phosphorylation, which only transiently increases their nuclear accumulation. In the nucleus, STAT proteins control the transcriptional activation and repression of associated genes by directly targeting DNA regulatory elements (DRE), which are usually found in the first introns of their target genes and in enhancer and promoter regions. Through chromatin immunoprecipitation followed by sequencing (ChIP-seq) and the integration of gain- or loss-of-function transcriptomics, it is possible to identify various STAT binding sites and target genes; e.g., MYC, BCL-2, and D-type cyclins, which are engaged by any STAT protein in various cell types [36,42].

2.2. JAK-STAT Activation

Based on the ligand, the receptor and their tissue specificity, distinct combinations of STATs and JAKs are activated. This canonical signaling is based on JAK-mediated STAT tyrosine-phosphorylation. Additionally, several non-canonical pathways have been described, including cascades building on the kinase-independent action of JAKs and unphosphorylated STATs, or the formation of higher-order or multifactorial STAT transcriptional complexes, which can also affect cytokine signaling and immune cell function [36,43]. The most common non-canonical pathway activators include, among others, the cytoplasmic non-receptor tyrosine kinases SRC and ABL (or BCR–ABL fusion proteins in Philadelphia chromosome (Ph+) leukemias), the platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) [41,44,45]. Compared to the genomic targets of the canonical STAT signaling pathway, which are predominantly composed of genes implicated in the development of cellular immunity, target sites of STATs of the non-canonical pathway were found to be rather associated with genes implicated in epigenetic regulation [46].
**Figure 1.** The JAK-STAT signaling pathway. The JAK-STAT pathway transmits signals from extracellular ligands (e.g., cytokines: IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-20, IL-21, IL-22, IL-23, IL-24, IL-27, IL-31, IFNα, IFNβ, IFNγ, IFNλ), GM-CSF, G-CSF, leptin; hormones: EPO, PRL, GH, TPO; growth factors: EGF, insulin, FGF, PDGF, VEGF) through an intracellular signaling cascade to the transcriptional machinery in the nucleus. Ligand-binding leads to a conformational change of the receptor and the activation of receptor-associated JAKs by autophosphorylation and/or transphosphorylation and subsequently the phosphorylation of the receptor tyrosine residues. This in turn provides a docking site for the STAT proteins and leads to their JAK-mediated phosphorylation. Activated STATs translocate as either homo- or heterodimers to the nucleus and regulate gene transcription. Then, expressed SOCS proteins act via negative feedback circuits by interacting competitively with receptors. JAK (Janus kinase), P (phosphorylation), STAT (signal transducer and activator of transcription), SOCS (suppressors of cytokine signaling), TYK2 (tyrosine kinase 2).
During canonical STAT signaling, STATs act mostly as homodimers, but they are also found as heterodimers or higher-order tetramers [36]. STAT1 and STAT2 are involved in IFN signaling. While STAT1 is implicated in anti-viral and -bacterial defense, tumor-growth inhibition and apoptosis, STAT2 participates in immunomodulatory and anti-apoptotic/proliferative signaling. JAK1 together with JAK2 is induced by IFN-γ and JAK1 together with TYK2 by type I and type III IFNs, making JAK1 imperative for IFN signaling [43]. IFN-γ induces exclusively the phosphorylation of STAT1, leading to its homodimerization and finally binding to gamma interferon-activated sites (GAS) of IFN-regulated genes. Type I IFN target genes are induced by heterodimers of STAT1 and STAT2, which, together with IRF9, form the interferon stimulated gene factor 3 (ISGF3) complex that regulates transcription via binding to interferon-stimulated response elements (ISREs) [41,47–49]. STAT3 is activated by numerous cytokines, including IL-6, IL-10 or hormones like prolactin and leptin, as well as growth factors like EGF, PDGF, fibroblast growth factor (FGF) and insulin-like growth factors (IGFs) [50]. It is engaged in immunity and inflammation but also in multiple other biological processes including immune response resolution, wound healing [51] and restoration of tissue integrity [52]. For example, IL-6 binds the IL-6 receptor and glycoprotein 130 (gp130) receptor β-subunit complex and activates JAK1, JAK2 and TYK2, leading to the formation of STAT3 homodimers [53–55]. Aberrant STAT3 signaling drives mitogenesis and anti-apoptotic pathways and furthermore tumorigenesis and metastasis [50]. STAT4 is inevitable for cellular-mediated immune response by regulating differentiation of Th1 cells, lymphocyte effector function and IFN-γ production [56,57]. IL-23 and IL-12 signal through JAK2 and TYK2 while IL-23 induces STAT3/STAT4 heterodimers and IL-12 signaling results in STAT4 homodimers [58]. Signaling via the two highly related STAT5 proteins, STAT5A and STAT5B, occurs primarily through JAK1 and JAK3 upon binding of IL-15, IL-7 and IL-2 to their respective receptors and the γc family of receptors [59]. Furthermore, STAT5 can be activated in a JAK2-dependent manner by prolactin (PRL), growth hormone (GH), erythropoietin (EPO) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [60]. STAT5A is predominantly expressed in the mammary gland where it is involved in PRL signaling, whereas STAT5B is mainly expressed in the liver and muscle, regulating GH signaling [61]. STAT5 is a key transcription factor contributing to the initiation and progression of various cancers, but under physiological conditions STAT5 signaling is imperative for hematopoiesis [62], lipid metabolism [63] and T lymphocyte [64] and natural killer (NK) cell development and function [65]. Similar to STAT5, STAT6 is activated by JAK1 and JAK3, but activation occurs via binding of IL-4 and IL-13 to their respective receptors and the γc family of receptors [66]. It is involved in the development of allergic inflammation, Th2-type responses [67], B and T cell proliferation and macrophage differentiation [68,69]. Besides classical STAT6 homodimerization, type I IFN-stimulated B cells induce the heterodimerization of STAT6 and STAT2 [70], whereas IL-4 promotes STAT6/STAT2 heterodimers in T cells [71].

2.3. JAK-STAT Inactivation

The JAK–STAT signaling cascade is subject to constant multiple levels of activating and inactivating processes, which offer new possibilities for increased therapeutic exploitation. Pathway inactivation can be accomplished by basic cellular mechanisms including posttranslational modifications, microRNAs, RNA-binding proteins [36], the ubiquitin-proteasome system [72] or receptor internalization through endocytosis [73]. Various protein tyrosine phosphatases (PTP) including Src (Sarcoma) Homology 2 Domain Phosphatase 1 and 2 (SHP1, SHP2), CD45 and T-cell protein tyrosine phosphatase (TCPTP), just to name a few, can hydrolyze phosphorylated JAKs, upstream receptors and STATs, both in cytoplasm as well as in the nucleus [74]. Protein inhibitor of activated STAT (PIAS) proteins are activation-suppressing proteins, which negatively regulate JAK-STAT signaling by inhibiting STAT phosphorylation, translocation or DNA binding [75]. The protein family of suppressors of cytokine signaling (SOCS) acts via negative feedback circuits. All eight SOCS proteins (SOCS1-7 and CIS) contain SH2 domains to interact competitively
with receptors [76,77]. Additionally, SOCS can recruit E3 ubiquitin ligases to induce Lysin 48-linked polyubiquitylation and subsequent proteasomal degradation of the receptor or the JAKs [78]. SOCS can also target JAKs’ substrate binding groove with high specificity, via their N-terminal kinase inhibitory region, which functions as a pseudo-substrate for JAKs [79].

2.4. Dysregulation of JAK-STAT Signaling in the Pathogenesis of AML

The complex network between genetic factors and extrinsically driven signaling pathways is crucial for tumorigenesis and other severe diseases. JAK-STAT signaling in the hematopoietic system tightly orchestrates survival and self-renewal of hematopoietic stem cells (HSC) and hematopoiesis, as well as proliferation. Thus, aberrant JAK-STAT signaling has been associated with the pathogenesis of inflammatory diseases and immunodeficiencies and also with hematopoietic malignancies [80,81]. Since the 1990s, mutations of proteins inducing the constitutive activation of JAK-STAT have been associated with AML [30,82–84]. Importantly, constitutive activation of STAT3 and STAT5, and also of STAT6, can function as a predictive and prognostic biomarker and has been correlated with severe disease outcomes in AML [26,84].

Constitutive activation of STATs has often been found in cancer cells as a result of deregulated signaling of the upstream JAK. A classic example is JAK2\(^{V617F}\), a somatic point mutation within the autoinhibitory pseudokinase (JH2) domain, resulting in constitutive activation of the JH1 domain and thus increased activation of JAK2 and downstream STATs [85]. JAK2\(^{V617F}\) appears in the majority of secondary AML cases resulting from myeloproliferative neoplasm (MPN), where it acts as a main driver mutation. Mutated JAK2 is only present in <5% of de novo AML patients [23,24].

In de novo AML, constitutive activation of STATs can be achieved by auto- and paracrine factors such as IL-6, decreased expression of negative regulators such as SOCS1 or activating mutations in other (non-JAK) upstream kinases such as FMS-like tyrosine kinase 3 (FLT3) [86]. FLT3 mutations, especially internal tandem duplication mutations (ITDs) of the extracellular juxtamembrane (JM) domain, are the most frequent genetic alterations in AML patients with a normal karyotype [13,87]. FLT3 regulates proliferation, differentiation and survival in both myeloid and lymphoid lineage development through STAT5 activation, as well as via PI3K and RAS signaling [88]. The FLT3-ITD induces constitutive activation of STAT5 independently of upstream JAK2 or SRC and is resistant to SOCS inhibition. While FLT3-WT activates STAT5 indirectly via the ERK pathway, the mutated FLT3 directly phosphorylates STAT5 [89].

FLT3 mutations frequently co-occur with alterations in the NPM1 gene, leading to a significantly worse prognosis [90]. Mutated NPM1 can translocate mutated FLT3 to the endoplasmic reticulum and enhance STAT5 activation [91], as well as MYC and BCL2 expression in a bromodomain-containing protein 4 (BRD4)-dependent manner [92]. However, phosphorylated STAT5 downregulates NPM1 expression via BRCA1-BARD1 ubiquitin ligase signaling in human erythroleukemic cells. In addition to the crucial role of STAT5, STAT3 also interacts with NPM1 and can transcriptionally enhance its expression [90]. FLT3-ITDs also combine with mutations of DNMT3A, which seems to lead to the worst prognosis for AML patients [13,93]. DNMT3A preserves DNA methylation patterns during replication [94] and mutated DNMT3A elevates the self-renewal capacity of HSC [95]. Increased DNMT3 activity has been correlated with activation of STAT5 and hypermethylation of the PTEN promoter in AML cells [96].

Another way in which the JAK-STAT pathway contributes to the pathogenesis of AML is the reliance of leukemic cells on its signaling. AML cells carrying CEBPA or CEBPA/CSF3R mutations are sensitive to the inhibition of the JAK-STAT pathway [97]. Similar sensitivity has been detected in AML cells expressing RUNX1–RUNXIT1 [98]. Furthermore, the gain of function mutation of the tyrosine kinase c-KIT (KIT/D816V) is frequently detected in AML patients [99,100] and is strongly associated with STAT3/STAT5 activation [26]. These data and several other studies highlight the role of STAT transcription
factors, especially STAT3, STAT5A and STAT5B, in AML. Our STRING analysis illustrates that among all STATs, STAT3 and STAT5 show the strongest connections to the most frequent AML drivers, underlining their contribution to AML pathogenesis (Figure 2). We therefore describe current approaches directly targeting STAT3 and STAT5 and their upstream kinases (JAKs, FLT3) in pre-clinical and clinical studies for AML.

**Figure 2.** Protein–protein association analysis of STAT proteins and driver mutations in de novo AML. Visualization of STRING protein–protein interaction network of STATs and frequently mutated genes in de novo AML. Analysis includes physical as well as functional interactions of publicly available data [101]. Orange lines show connections of STAT3 or STAT5. The fill color of the nodes represents the mutation frequency of the genes [102]. The line width refers to the STRING interaction score with a confidence cut-off score of 0.7. Connections/protein–protein associations between STATs are illustrated in grey. STAT5A and STAT5B showed the same interactions and were therefore merged to STAT5 for clarity of the figure.

### 3. JAK Inhibitors

Inhibition of JAK-STAT signaling via JAK1/2 inhibitor Ruxolitinib is a successful approach in the treatment of MPNs. In rare cases MPNs evolve to secondary AML (sAML), which provided the first rationale for investigating Ruxolitinib as a treatment for sAML [103–107]. The understanding of the mutational landscape and its signaling consequences led to the identification of hyperactivity of the JAK-STAT pathway in many AML subtypes, independent of the JAK2\(^{V617F}\) mutation [86]. Therefore, Ruxolitinib and other JAK inhibitors are nowadays tested in AML preclinical settings with some having reached clinical trials (Table 1, Figure 3).
Table 1. Current clinical trials of JAK inhibitors in AML.

| Drug                  | Diseases                              | Trials                                      | References |
|-----------------------|---------------------------------------|---------------------------------------------|------------|
| JAK1/JAK2             |                                       |                                             |            |
| Ruxolitinib (INCBI8424) | AML, ALL, MDS, CML                    | Phase II                                   | [108]      |
|                       | MPN, AML                              | Phase II                                   |            |
|                       | Combination with Decitabine           |                                             |            |
|                       | AML, ALL, MDS, CML                    | Phase II                                   | [108]      |
|                       | AML in CR                             | Phase II                                   |            |
|                       | Combination with Decitabine           |                                             |            |
|                       | post MDS-AML                          | Phase I/II                                 |            |
|                       | Combination with Cytarabine           |                                             |            |
|                       | relapsed/refractory post-MPN AML      | Phase I/II                                 |            |
|                       | Combination with Decitabine           |                                             |            |
|                       | MPN, post-MPN AML                     | Phase I/II                                 |            |
|                       | Combination with Decitabine           |                                             |            |
|                       | post-MDS AML, recurrent/refractory AML | Phase I                                    |            |
|                       | Combination with Venetoclax           |                                             | [114]      |
|                       | Leukemia, MPD, solid tumor            | Phase I                                    | [115]      |
| JAK2/FLT3             |                                       |                                             |            |
| Fedratinib (TG101348) | AML with FLT3 mutation                | Phase II                                   |            |
|                       | Combination with Decitabine           |                                             | [109]      |
|                       | AML with FLT3 mutation                | Phase II                                   |            |
|                       | Combination with standard treatment   |                                             | [116]      |
|                       | AML with FLT3 mutation                | Phase II                                   |            |
|                       | Combination with standard treatment   |                                             | [117]      |
|                       | AML with FLT3 mutation                | Phase I                                    |            |
|                       | Combination with standard treatment   |                                             | [118]      |
|                       | AML, CML, MDS                         | Phase I/II                                 |            |
|                       | Combination with standard treatment   |                                             | [119]      |
|                       | Monotherapy                           |                                             | [120]      |

AML (acute myeloid leukemia), CML (chronic myeloid leukemia), CR (complete remission), MDS (myelodysplastic syndrome), MPD (myeloproliferative disorder), MPN (myeloproliferative neoplasm). Clinical trials were searched on clinicaltrials.gov (June 2021) and included based on the following criteria: JAK inhibitors in AML, exclusion criteria: terminated, withdrawn, suspended, or status unknown.

Ruxolitinib has been approved for the treatment of intermediate and high-risk MPNs that are resistant or intolerant to hydroxyurea. In MPN, inhibition of JAK1/2 as a monotherapy efficiently reduces symptoms [107]. Unfortunately, in the heterogeneous AML patient cohort, the anti-leukemic activity of Ruxolitinib as a single agent has been rather poor [121,122]. However, preclinical models of pediatric acute megakaryoblastic leukemia (AMKL) with enhanced activity but no known driver mutation in the JAK-STAT pathway revealed Ruxolitinib as an effective drug [123]. This suggests that Ruxolitinib’s treatment efficacy as single agent may be improved by a more personalized approach. Another strategy to increase the therapeutic effect of Ruxolitinib in AML is the combination with other agents. Decitabine, a DNA methylation inhibitor [124], was discovered to be very effective in combination with Ruxolitinib in a mouse model of AML, driven by genetic knockout of p53 and JAK2V617F mutation [125]. This combinatorial approach was further implemented in clinical trials where it demonstrated a promising 29–42% of complete remission (CR) and complete remission with incomplete hematologic recovery (CRI) during phase I/II trials in patients with post-MPN AML. However, the overall survival remained poor [126–128]. Final results of the clinical trial are still awaited; however, the authors suggest that this approach could be an alternative to aggressive chemotherapy for obtaining CR prior to allogenic hematopoietic stem cell transplant [127]. A recent approval of a combination of Decitabine with BCL2 inhibitor Venetoclax, which is also directed to AML patients who are not eligible for intensive chemotherapy, diminishes the attractiveness of this novel combinatorial approach of Ruxolitinib and Decitabine [127,129]. In particular, preclinical studies have shown promising results upon combining Venetoclax with Ruxolitinib. In
Among many combinatorial approaches being tested in preclinical settings, a combination of Ruxolitinib with Lysine Specific Demethylase 1 (LSD1) inhibitor recently demonstrated a synergistic survival improvement in mouse models of CEBPA- and CSF3R-mutated AML [97]. LSD1 demethylates histones H3K4 and H3K9, resulting in transcriptional regulation, and its inhibition alone induces differentiation in a subset of AML cell lines [131]. The effect is profoundly enhanced by combination with Ruxolitinib [97].

Lestaurtinib is a multikinase inhibitor initially developed as a tropomyosin receptor kinase A (TrkA) inhibitor, which also potently inhibits JAK2 and FLT3 [132]. FLT3-mutated AML cells are sensitive to Lestaurtinib in vitro upon treatment with chemotherapeutic agents [133,134]. The same approach was shown to be effective in vivo in a murine model of FLT3-ITD AML [134]. On this basis, Lestaurtinib was assessed in clinical trials in combination with classical chemotherapy in patients with relapsed FLT3-mutated AML. Although a transient response appeared in treated patients, overall, no clinical efficacy was observed in this therapeutic setting [135].

Pacritinib is a multikinase inhibitor with high specificity towards JAK2 over other JAKs, but in addition it inhibits interleukin receptor-associated kinase (IRAK), Colony stimulating factor 1 receptor (CSF1R) and FLT3 [136]. It is currently undergoing phase II/III clinical trials for MPNs. Pacritinib not only effectively inhibits the growth of many FLT3-ITD+ AML cell lines, but combined inhibition of JAK2 and FLT3 also overcomes the resistance towards FLT3 inhibitors (e.g., Sunitinib), which is often associated with overactivation of the JAK-STAT pathway [137]. Interestingly, a more recent report identified
Pacritinib as being effective in AML mouse models and patient samples irrespective of the mutational status of FLT3 and JAK2. The therapeutic effect was attributed to efficient IRAK1 inhibition rendering this kinase a novel target in AML [138]. Indeed, a combined treatment regimen of Pacritinib and chemotherapy was well tolerated and demonstrated preliminary anti-leukemic activity in patients with FLT3 mutations [139].

Fedratinib is another small molecule targeting JAK2 and FLT3, which has recently been approved for the treatment of MPN. In addition, Fedratinib inhibits BRD4 [140]. Preclinical studies identified Fedratinib to be effective in reducing the leukemic burden in xenograft models as a single agent and resulting in a stronger anti-leukemia response in combination with cytarabine [141]. Similarly to Ruxolitinib, Fedratinib is currently undergoing phase II clinical trials in AML in combination with Decitabine, but no results are available yet.

Momelotinib is a JAK1/2 inhibitor that has reached phase III clinical trials for MPNs [142,143]. Although limited data exist concerning the effectiveness of Momelotinib in AML, it has been shown to effectively inhibit the growth of AML cell lines and disease progression in a xenograft model. Interestingly, the anti-leukemic effect was attributed to the inhibition of the kinase IKBKE, a noncanonical IkB kinase, which drives MYC expression [144]. Momelotinib, similarly to other JAK2 inhibitors, also shows inhibitory activity against FLT3. A recent study using AML cell lines and mouse models of FLT3 mutated AML suggests that Momelotinib-mediated combinatorial inhibition of JAK1/2, FLT3 and downregulation of MYC will be more effective than currently used FLT3 tyrosine kinase inhibitors (TKIs) [145].

Inhibition of JAKs in combination with chemotherapy or epigenetic modulator inhibitors seems to be a promising approach in the treatment of different subtypes of AML. In contrast to MPNs, where the specific JAK2 inhibitors sparing other kinases are discussed as the best treatment option [146], AML patients seem to benefit more from multikinase inhibitors, which, in addition to JAK-STAT, target another pathway(s). This approach is especially successful in FLT3 mutated AML. Although occurring with significantly lower incidences, many other mutations in AML drive constitutive activation of the JAK-STAT pathway [86]. Therefore, further studies identifying new targets resulting in synergistic effects and finding new combinatorial inhibitors are required.

4. STAT Inhibitors

A substantial proportion of AML patients harbor mutations that cause hyperactivation of JAK-STAT signaling [147]; therefore, great effort has been put into the development of inhibitors that block phosphorylation mediated by JAKs, which have already been shown to efficiently achieve indirect STAT inhibition [86]. However, many TKIs showed off-targets besides JAKs, potentially causing more side effects that could be prevented by targeting downstream proteins relevant for leukemogenesis [148]. Furthermore, JAK-independent mechanisms activating STATs were also identified [149–151]. Therefore, direct interference with STATs remains an attractive therapeutic approach. Unlike other STAT family members, STAT3 and STAT5 have been extensively studied in hematopoietic malignancies and were shown to be key factors in AML. In most AML patient samples of peripheral blood or bone marrow, constitutive activation of STAT3 and/or STAT5 was observed [30,32,33,152]. Therefore, we will focus on those STAT family members and summarize the current strategies in the development of inhibitors in the context of AML (Table 2, Figures 2 and 3).
Table 2. STAT inhibitors investigated in AML.

| Drug              | Type            | Target        | Diseases                        | Trials                                                                 | References |
|-------------------|-----------------|---------------|---------------------------------|------------------------------------------------------------------------|------------|
| OPB-51602         | Small molecule  | SH2 domain    | AML, MM, NHL, ALL, CML          | Phase I                                                               | [120]      |
| BBI-608           | Small molecule  |               | MM, Lymphoma, AML, MDS, CML, CLL| Phase I                                                               | [153]      |
| C188-9            | Small molecule  | SH2 domain    | AML                             | Preclinical                                                            | [154]      |
| SD-36             | PROTAC          | SH2 domain    | AML, ALCL                       | Preclinical                                                            | [155]      |
| AZD9150           | ASO             | mRNA          | AML, MDS, DLBCL, HL, NHL        | Preclinical                                                            | [156,157]  |
| CpG-STAT3-siRNA   | siRNA           | mRNA          | AML, MM                         | Preclinical                                                            | [158]      |
| CpG-STAT3dODN     | Decoy oligo-nucleotide | DBD | AML                             | Preclinical                                                            | [159]      |
| AC-4-130          | Small molecule  | SH2 domain    | AML, CML                        | Preclinical                                                            | [27]       |
| BP-1-107          | Small molecule  | SH2 domain    | AML, CML                        | Preclinical                                                            | [160]      |

4.1. STAT3

STAT3 has been shown to play an important role during myeloid homeostasis and differentiation as well as proliferation [161,162]. Due to its ability to block myeloid differentiation, its crucial role during leukemogenesis is highlighted [154,163]. Target genes of STAT3 driving survival and proliferation include MYC, cyclin D1, BIRC5 (Survivin) and BCL2. In line, upregulation of STAT3 is associated with protection from apoptosis [164]. Furthermore, constitutive STAT3 activity is associated with adverse patient outcomes [165] and significantly reduced disease-free survival in AML patients [33]. STAT3 signaling is frequently altered due to activating mutations [166,167] or constitutive stimulation of upstream signaling [34]. Based on those findings, STAT3 has become an attractive therapeutic target in AML.

A small molecule targeting the SH2 domain of STAT3, OPB-51602, has entered clinical trials for the treatment of hematological malignancies. It was shown to efficiently repress proliferation by blocking the phosphorylation sites tyrosine705 and serine727 of STAT3 in various human cancer cell lines [168]. More recent studies revealed that the inhibitor in particular interferes with the mitochondrial function of STAT3, which was demonstrated in human cancer cell lines in vitro [169]. In this phase I study, 20 patients with relapsed or refractory hematological malignancies were treated daily based on the “3 + 3” design. Besides being safe and well tolerated, common adverse events such as nausea, peripheral sensory neuropathy and diarrhea were reported. Nevertheless, no clear therapeutic response was obtained in this patient cohort, except two AML patients and one myeloma patient that were reported with durable stable disease. However, the authors claim that the optimal dose and daily dosing schedule for long-term administration was difficult to
determine in this heterogeneous patient cohort, which thus suggests a need for further investigation in a different patient group [170].

The small molecule STAT3 inhibitor, C188-9, was demonstrated to inhibit G-CSF-induced STAT3 activation thereby efficiently inducing apoptosis in primary pediatric AML samples and AML cell lines [154]. The compound targets the phosphotyrosine (pY) peptide binding site within the SH2 domain, subsequently preventing the interaction with tyrosine kinases and dimerization. However, further studies mainly focused on its antitumor activity in solid cancer such as head and neck squamous cell carcinoma [171] and pancreatic cancer [172] demonstrating its potential to impair tumor growth in vitro.

BBI608, also known as Napabucasin, is a small molecule inhibitor blocking STAT3-mediated gene transcription, whose antitumorigenic properties have been demonstrated in phase Ib/II and phase II trials in solid cancers as a monotherapy and in combination with standard treatment [173,174]. Recently, BBI608 was also shown to exhibit anti-leukemic effects in human AML cell lines in vitro as well as in primary AML samples obtained from 21 patients. In this study, BBI608 treatment led to a promising decrease in tumor burden in an in vivo AML xenograft model using the human AML cell line MOLM-13. Furthermore, combination treatment of BBI608 together with Venetoclax demonstrated enhanced cytotoxicity in BBI608-resistant Kasumi-1 cells [175]. Taken together, these data suggest BBI608 as a potential candidate for treatment in AML; however, this requires further evaluation.

An emerging strategy to target proteins with small-molecule degraders are proteolysis targeting chimeras (PROTACs), which rely on hijacking the cellular degradation machinery, the proteasome. By using a heterobifunctional degrader, the protein of interest is linked to an E3 ligase, which subsequently leads to polyubiquitination and degradation of the target [176]. Due to this interplay, PROTACs are considered to have high selectivity. Recently, a PROTAC called SD-36 was shown to selectively induce degradation of STAT3 over all other STATs in vitro and in vivo [155]. SD-36 consists of lenalidomide, a CRBN ligand analog, and the STAT3 inhibitor SI-109, which recognizes the SH2 domain of STAT3. In this study, SD-36 efficiently degrades STAT3 in vitro in various leukemia and lymphoma cell lines. Besides inducing tumor regression in a MOLM-16 dependent xenograft tumor model, it was also well tolerated in the in vivo setting. SD-36 is the first PROTAC targeting STAT3, which demonstrates that modestly selective inhibitors such as SI-109 can also be improved by using advanced technologies.

An attractive strategy that emerged with the fast progress of next-generation sequencing techniques involves antisense oligonucleotide (ASO) inhibitors, which are designed based on the genetic sequence of the target gene. One promising STAT3 ASO, AZD9150, showed efficiency when systemically administered in preclinical trials for lymphoma and lung cancer (NSCLC) patients [156]. In vitro, AZD9150 achieved a decrease in STAT3 expression without affecting STAT1 and STAT5 levels in various human cancer cell lines. A further phase Ib trial with 30 relapsed or refractory non-Hodgkin’s lymphoma patients was undertaken, which identified DLBL patients as the best responding group [157]. Recently, AZD9150 was shown to promote hematopoietic differentiation in primary MDS and AML samples, also supporting its rationale for AML [177].

As a driver of immune evasion in cancer it is conceivable that inhibition of STAT3 enhances anti-tumor immune responses. Thus, Hossain et al. investigated small interfering RNAs (siRNAs) conjugated to cytosine guanine dinucleotides (CpG) that target STAT3 gene silencing. To deliver the inhibitor to Toll-like Receptor (TLR)-9 positive antigen-presenting immune cells, the inhibitor molecule was linked to a TLR9 ligand and a CpG [158]. Administration of CpG-STAT3 siRNA in a mouse model mimicking human inv(16) AML resulted in disease regression in a CD8+ T-cell-dependent manner. Furthermore, STAT3 silencing/TLR9 triggering led to enhanced immunogenicity of primary AML cells. Based on this immunostimulatory strategy, the decoy oligodeoxynucleotide (dODN) inhibitor CpG-STAT3dODN was shown to block transcriptional activity of STAT3 by acting as a DNA decoy molecule sequestering STAT3 in the cytoplasm. Xenografts using 14 AML patient-
derived samples showed efficient immune-mediated eradication by CD8/CD4+ T cells in mice. However, it could not be excluded that CpG-STAT3dODN can also partially block STAT1 [159]. Nevertheless, this strategy based on the enhancement of T cell response might not only be of clinical relevance for AML but also for other hematological malignancies.

4.2. STAT5

STAT5 plays a pivotal role especially in AML patients who harbor fusion-oncogenes such as BCR-ABL and FLT3-ITD, which contribute to its constitutive activation [32]. For AML patients harboring FLT3-ITD, which is one of the most commonly detected cytogenetic abnormalities, several upstream inhibitors targeting FLT3 kinase achieved promising clinical outcomes [178]. Thus, the majority of pharmacological interventions targeting STATs have focused on STAT3 and not STAT5. Two of those TKIs, namely Midostaurin and Gilteritinib, were also approved by the FDA for the treatment of FLT3 mutated AML [179,180]. Although FLT3 inhibitors are nowadays part of standard therapy in FLT3 mutated AML patients, the occurrence of therapy resistance is an ongoing challenge. Thus, using several approaches to target a disrupted signaling pathway might be an efficient strategy to eradicate leukemic cells and prevent therapy resistance.

In 2012, Page et al. performed an in vitro screen focusing on salicylic acid-containing inhibitors potentially serving as phosphotyrosine mimicry to the SH2 domain of STATs [160]. Two of the lead compounds, BP-107 and BP-108, showed high binding affinity to STAT5 and efficiently suppressed its phosphorylation. Evaluation on the BCR-ABL positive K562 (CML) and FLT3-ITD positive MV-4-11 (AML) human cell lines revealed effective suppression of STAT5 phosphorylation and downregulation of target genes such as Cyclin D1, Cyclin D2, C-MYC and MCL-1. Further compounds, SF-1-087 and SF-1-088, were identified, which also showed high selectivity for STAT5 over STAT3 and STAT1.

As a novel SH2 inhibitor of STAT5, AC-4-130 was demonstrated to efficiently diminish STAT5 activity in human AML cells lines and primary FLT3-ITD-driven AML cells. In this preclinical setting, AC-4-130 exhibited anti-leukemic activity in vitro and in vivo in a xenograft model based on MV-4-11 cells by selectively targeting STAT5 over STAT1 and STAT3. Furthermore, it showed enhanced efficiency in combination with Ruxolitinib [27].

5. Conclusions and Outlook

To summarize, various strategies for the inhibition of deregulated JAK-STAT signaling have demonstrated promising results in vitro and in mouse models with some compounds reaching clinical trials for AML. However, the heterogenicity behind AML development and progression might be an explanation for the diverse treatment outcomes. To address this, a better understanding of the complex biology and the underlying mechanisms involved in JAKs and STATs modulating AML progression is needed. For example, a recent preclinical study identified strong dependency of rarely occurring MLL-AF10-driven AML on JAK1 [86]. Thus, personalized approaches and identification of predictive biomarkers might improve the therapeutic benefit from JAK inhibition. Due to their multifunctionality as transcription factors, STAT proteins also have divergent functions depending not only on the AML subtype. In the case of STAT3, it was shown that the two alternatively spliced isoforms can have opposite roles in leukemogenesis [35], making it even more challenging to predict the effects of STAT3 targeting. Further, as emerging chemoresistance in leukemic cells is an ongoing challenge, which is reflected in the high relapse rate, it is important to interfere with cancer drivers on different levels. As illustrated by the example of JAK inhibitors, the most successful compounds are those that in addition to JAKs target another pathway (e.g., FLT3). Such kinase inhibitors, as well as combinational treatment of JAK or STAT inhibitors with other compounds, would be the best strategy to eliminate leukemic cells efficiently before they develop resistance. Ruxolitinib-based combinatory therapies are continuously increasing according to clinical needs. This is the best-studied JAK1/2 inhibitor, but it did not fulfill expectations as a single agent due to modest antileukemic activity in patients [121,122]. However, in combination with Decitabine [109,112,113,124]
and also with Cytarabine [111], Venetoclax [114] or the STAT5 inhibitor AC-4-130 [27], it showed promising results and increased AML treatment efficacy. Overall, clinical trial efforts and financial incentives in the last decade have intensified the research on potential therapies and have led to a surge in potential clinical applications and approvals. Ongoing development of new JAK-STAT inhibitors with higher compound selectivity and better disease-specificity is central to the management of AML.

Author Contributions: Writing—review and editing, B.M., S.E. and A.W.-S. Conceptualization, D.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Austrian Science Fund (FWF) under grant P32693 to D.S. and Gesellschaft für Forschungsförderung Niederösterreich m.b.H. (GFF) under grant SC19-019 to D.S.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: All authors accept Open Access Funding by the Austrian Science Fund (FWF).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Colmone, A.; Amorim, M.; Pontier, A.L.; Wang, S.; Jablonski, E.; Sipkins, D.A. Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells. *Science* 2008, 322, 1861–1865. [CrossRef]
2. De Kouchkovsky, I.; Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. *Blood Cancer J.* 2016, 6, e441. [CrossRef] [PubMed]
3. National Cancer Institute. *Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia*; National Cancer Institute: Bethesda, MD, USA, 2020.
4. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. *CA Cancer J. Clin.* 2021, 71, 7–33. [CrossRef]
5. Shah, A.; Andersson, T.M.-L.; Rachet, B.; Björkholm, M.; Lambert, P. Survival and cure of acute myeloid leukemia in England, 1971–2006: A population-based study. *Br. J. Haematol.* 2013, 162, 509–516. [CrossRef]
6. Thein, M.S.; Ershler, W.B.; Jemal, A.; Yates, J.W.; Baer, M.R. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. *Cancer* 2013, 119, 2720–2727. [CrossRef] [PubMed]
7. Desai, P.; Trinchant, N.M.; Savenkov, O.; Simon, M.S.; Cheang, G.; Lee, S.; Samuel, M.; Ritchie, E.K.; Guzman, M.L.; Ballman, K.V.; et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. *Nat. Med.* 2018, 24, 1015–1023. [CrossRef] [PubMed]
8. Alonso, C.M.; Llop, M.; Sargas, C.; Pedrola, L.; Panadero, J.; Hervás, D.; Cervera, J.; Such, E.; Ibáñez, M.; Ayala, R.; et al. Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. *J. Mol. Diagn.* 2018, 21, 228–240. [CrossRef] [PubMed]
9. Mack, E.K.M.; Marquardt, A.; Langer, D.; Ross, P.; Ueltsch, A.; Kiehl, M.G.; Mack, H.I.D.; Haferlach, T.; Neubauer, A.; Brendel, C. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing. *Haematologica* 2019, 104, 277–287. [CrossRef]
10. Abelson, S.; Collord, G.; Ng, S.W.K.; Weissbrod, O.; Cohen, N.M.; Niemeyer, E.; Barda, N.; Zuzarte, P.C.; Heisler, L.; Sundaravadanam, Y.; et al. Prediction of acute myeloid leukemia risk in healthy individuals. *Nature* 2018, 559, 400–404. [CrossRef]
11. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016, 127, 2391–2405. [CrossRef]
12. Song, X.; Peng, Y.; Wang, X.; Chen, Y.; Jin, L.; Yang, T.; Qian, M.; Ni, W.; Tong, X.; Lan, J. Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001–2013. *Acta Haematol.* 2018, 139, 115–127. [CrossRef] [PubMed]
13. Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2016, 374, 2209–2221. [CrossRef]
14. Lagunas-Rangel, F.A.; Chávez-Valencia, V.; Gómez-Guioja, M.A.; Cortes-Penagos, C. Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis. *Int. J. Hematol. Stem Cell Res.* 2017, 11, 328–339.
15. Gilliland, D.G.; Griffin, J.D. The roles of FLT3 in hematopoiesis and leukemia. *Blood* 2002, 100, 1532–1542. [CrossRef]
16. Yuan, Y.; Zhou, L.; Miyamoto, T.; Iwasaki, H.; Harakawa, N.; Hetherington, C.J.; Burel, S.A.; Lagasse, E.; Weissman, I.L.; Akashi, K.; et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. USA 2001, 98, 10398–10403. [CrossRef]

17. Kelly, L.M.; Gilliland, D.G. Genetics of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 2002, 3, 179–198. [CrossRef]

18. Becker, H.; Pfeifer, D.; Afonso, J.D.; Nimer, S.D.; Veelken, H.; Schwab, M.; Lübbert, M. Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: Models for the ‘second hit’ hypothesis. Leukemia 2008, 22, 1792–1794. [CrossRef]

19. Kihara, R.; Nagata, Y.; Kiyoi, H.; Kato, T.; Yamamoto, E.; Suzuki, K.; Shen, F.; Asou, N.; Ohtake, S.; Miyawaki, S.; et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014, 28, 1586–1595. [CrossRef]

20. Dhall, A.; Zee, B.; Yan, F.Y.; Blanco, M.A. Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia. Front. Oncol. 2019, 9, 432. [CrossRef] [PubMed]

21. Abdel-Wahab, O.; Levine, R.L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013, 121, 3563–3572. [CrossRef]

22. Schindler, C.; Levy, D.; Decker, T. JAK-STAT Signaling: From Interferons to Cytokines. J. Biol. Chem. 2007, 282, 20059–20063. [CrossRef]

23. Lee, J.W.; Kim, Y.G.; Soung, Y.H.; Han, K.J.; Kim, S.Y.; Rhim, H.; Min, W.S.; Nam, S.W.; Park, W.S.; Yoo, N.J.; et al. The JAK2 V617F mutation in de novo acute myelogenous leukaemias. Oncogene 2005, 25, 1434–1436. [CrossRef]

24. Hidalgo-López, J.E.; Kanagal-Shamanna, R.; Medeiros, L.J.; Estrov, Z.; Yin, C.C.; Verstovsek, S.; Konoplev, S.; Jorgensen, J.L.; Mohammad, M.M.; Miranda, R.N.; et al. Morphologic and Molecular Characteristics of De Novo AML With JAK2V617F Mutation. J. Natl. Compr. Canc Netw. 2017, 15, 790–796. [CrossRef] [PubMed]

25. Gleixner, K.V.; Schneeweiss, M.; Eisenwort, G.; Berger, D.; Herrmann, H.; Blatt, K.; Greiner, G.; Byrgazov, K.; Hoermann, G.; Konopleva, M.; et al. Combined targeting of STAT3 and STAT5: A novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica 2017, 102, 1519–1529. [CrossRef]

26. Brachet-Botineau, M.; Polomski, M.; Neubauer, H.; Juen, L.; Hédou, D.; Viaud-Massuard, M.-C.; Prié, G.; Guilleux, F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers 2020, 12, 240. [CrossRef] [PubMed]

27. Wingelhofer, B.; Maurer, B.; Heyes, E.C.; Cumarasawamy, A.A.; Berger-Bevcvar, A.; De Araujo, E.D.; Orlowa, A.; Freund, P.; Ruge, F.; Park, J.; et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia 2018, 32, 1135–1146. [CrossRef] [PubMed]

28. Ma, J.-H.; Qin, L.; Li, X. Role of STAT3 signaling pathway in breast cancer. Cell Commun. Signal. 2020, 18, 1–13. [CrossRef]

29. Ghoshal Gupta, S.; Baumann, H.; Wetzler, M. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leuk. Res. 2008, 32, 1005–1014. [CrossRef]

30. Guilleux-Gruart, V.; Guilleux, F.; Desaint, C.; Claissé, J.F.; Capiod, J.C.; Delobel, J.; Weber-Nordt, R.; Dusanser-Fourt, I.; Dreyfus, F.; Groner, B.; et al. STAT-related transcription factors are constitutively activated in peripheral. Blood 1996, 87, 1692–1697. [CrossRef]

31. Cook, A.; Li, L.; Ho, Y.; Lin, A.; Stein, A.; Forman, S.; Perrotti, D.; Jove, R.; Bhatia, R. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood 2014, 123, 2826–2837. [CrossRef]

32. Birkenkamp, K.; Geugien, M.; Lemmink, H.; Kruijer, W.; Vellenga, E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001, 15, 1923–1931. [CrossRef]

33. Benekli, M.; Xia, Z.; Donohue, K.A.; Ford, L.A.; Pixley, L.A.; Baer, M.R.; Baumann, H.; Wetzler, M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99, 252–257. [CrossRef]

34. Xia, Z.; Sait, S.N.; Baer, M.R.; Barcos, M.; Donohue, K.A.; Lawrence, D.; Ford, L.A.; Block, A.M.W.; Baumann, H.; Wetzler, M. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk. Res. 2001, 25, 473–482. [CrossRef]

35. Aigner, P.; Mizutani, T.; Horvath, J.; Eder, T.; Heber, S.; Lind, K.; Just, V.; Moll, H.P.; Yeroslaviz, A.; Fischer, M.J.M.; et al. STAT3beta is a tumor suppressor in acute myeloid leukemia. Blood Adv. 2019, 3, 1989–2002. [CrossRef] [PubMed]

36. Villarino, A.V.; Kanno, Y.; O’Shea, J.I. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat. Immunol. 2017, 18, 374–384. [CrossRef]

37. Thomis, D.C.; Berg, L.J. The role of Jak3 in lymphoid development, activation, and signaling. Curr. Opin. Immunol. 1997, 9, 541–547. [CrossRef]

38. Ferrao, R.; Lupardus, P.J. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions. Front. Endocrinol. 2017, 8, 71. [CrossRef] [PubMed]

39. Lupardus, P.J.; Uitlsch, M.; Wallweber, H.; Kohli, P.B.; Johnson, A.R.; Eigenbrot, C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. USA 2014, 111, 8025–8030. [CrossRef] [PubMed]

40. Saharinen, P.; Silvennoinen, O. The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction. J. Biol. Chem. 2002, 277, 47954–47963. [CrossRef] [PubMed]

41. Verhoeven, Y.; Tilborgs, S.; Jacobs, J.; De Waele, J.; Quatannens, D.; Deben, C.; Prehen, S.; Pauwels, P.; Trinh, X.B.; Wouters, A.; et al. The potential and controversies of targeting STAT family members in cancer. Semin. Cancer Biol. 2020, 60, 41–56. [CrossRef]
42. Wingelhofer, B.; Neubauer, H.A.; Valenti, P.; Han, X.; Constantinescu, S.N.; Gunning, P.T.; Mühler, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. *Leukemia* 2018, 32, 1713–1726. [CrossRef]

43. Majoros, A.; Platanitis, E.; Kernbauer-Hülzl, E.; Rosebrock, F.; Müller, M.; Decker, T. Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses. *Front. Immunol.* 2017, 8, 29. [CrossRef]

44. Haura, E.B.; Turkson, J.; Jove, R. Mechanisms of Disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat. Clin. Pr. Oncol.* 2005, 2, 315–324. [CrossRef]

45. Ram, P.T.; Iyengar, R. G protein coupled receptor signaling through the Src and Stat3 pathway: Role in proliferation and transformation. *Oncogene* 2001, 20, 1601–1606. [PubMed] [CrossRef]

46. Wang, W.; Wang, L.; Zha, B. The roles of STAT6 in regulating B cell fate, activation, and function. *Immunol. Res.* 2020, 201, 1543–1553. [CrossRef]

47. Junttila, I.S. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. *Curr. Opin. Immunol.* 2016, 38, 89–92. [PubMed]

48. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Immunol. Lett.* 2005, 2, 1713–1726. [CrossRef] [PubMed]

49. Bacon, C.; Petricoin, E.F.; Ortaldo, J.R.; Rees, R.C.; Larner, A.C.; Johnston, J.A.; O’Shea, J.J. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. *J. Exp. Med.* 2000, 192, 92–95. [CrossRef] [PubMed]

50. Salas, A.; Hernandez-Rocha, C.; Duijvvestein, M.; Faubion, W.; McGovern, D.; Vermeire, S.; Vetrono, S.; Casteele, N.V. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. *Nat. Rev. Gastroenterol. Hepatol.* 2020, 17, 323–337. [CrossRef]

51. Lutticken, C.; Wegenka, U.; Yuan, J.; Buschmann, J.; Schindler, C.; Ziemiecki, A.; Harpur, A.; Wilks, A.; Yasukawa, K.; Taga, T.; et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. *Science* 1994, 219, 89–92. [PubMed] [CrossRef]

52. Stahl, N.; Boullon, T.; Farruggella, T.; Ip, N.; Davis, S.; Witthuhn, B.; Quelle, F.; Silvennoinen, O.; Barbieri, G.; Pellegrini, S.; et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. *Science* 1994, 263, 967–968. [PubMed] [CrossRef]

53. Wingelhofer, B.; Neubauer, H.A.; Valenti, P.; Han, X.; Constantinescu, S.N.; Gunning, P.T.; Mühler, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. *Leukemia* 2018, 32, 1713–1726. [CrossRef]

54. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Immunol. Lett.* 2005, 2, 1713–1726. [CrossRef] [PubMed]

55. Bacon, C.; Petricoin, E.F.; Ortaldo, J.R.; Rees, R.C.; Larner, A.C.; Johnston, J.A.; O’Shea, J.J. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. *J. Exp. Med.* 2000, 192, 92–95. [CrossRef] [PubMed]

56. Bacon, C.; Petricoin, E.F.; Ortaldo, J.R.; Rees, R.C.; Larner, A.C.; Johnston, J.A.; O’Shea, J.J. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. *Proc. Natl. Acad. Sci. USA* 1995, 92, 7307–7311. [CrossRef] [PubMed]

57. Kaplan, M.H. STAT4: A Critical Regulator of Inflammation In Vivo. *Immunol. Res.* 2005, 31, 231–242. [PubMed] [CrossRef]

58. Kaplan, M.H. STAT4: A Critical Regulator of Inflammation In Vivo. *Immunol. Res.* 2005, 31, 231–242. [CrossRef]

59. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat. Rev. Immunol.* 2005, 5, 521–531. [CrossRef] [PubMed] [CrossRef]

60. Hennighausen, L.; Robinson, G.W. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. *Genes Dev.* 2008, 22, 711–721. [PubMed] [CrossRef]

61. Recio, C.; Guerra, B.; Guerra-Rodriguez, M.; Aranda-Rodriguez, H.; Martín-Rodriguez, P.; De Mirecki-Garrido, M.; Brito-Casillas, Y.; García-Castellano, J.M.; Estévez-Braun, A.; Fernández-Pérez, L. Signal transducer and activator of transcription (STAT)-5: An opportunity for drug development in oncohematology. *Oncogene* 2019, 38, 4657–4668. [PubMed] [CrossRef]

62. Haura, E.B.; Turkson, J.; Jove, R. Mechanisms of Disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat. Clin. Pr. Oncol.* 2016, 10, 2950. [CrossRef] [PubMed]

63. Junttila, I.S. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. *Front. Immunol.* 2018, 9, 888. [PubMed] [CrossRef]

64. Heltemes-Harris, L.M.; Farrar, M.A. The role of STAT5 in lymphocyte development and transformation. *Curr. Opin. Immunol.* 2012, 24, 146–152. [CrossRef]

65. Gotthardt, D.; Trifinopoulos, J.; Sexl, V.; Putz, E.M. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. *Front. Immunol.* 2019, 10, 2590. [PubMed] [CrossRef]

66. Wang, W.; Wang, L.; Zha, B. The roles of STAT6 in regulating B cell fate, activation, and function. *Immunol. Lett.* 2021, 233, 87–91. [CrossRef] [PubMed] [CrossRef]
69. Martinez, F.O.; Helming, L.; Gordon, S. Alternative Activation of Macrophages: An Immunologic Functional Perspective. *Annu. Rev. Immunol.* 2009, 27, 451–483. [CrossRef] [PubMed]

70. Gupta, S.; Jiang, M.; Pernis, A.B. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. *J. Immunol.* 1999, 163, 3834–3841. [PubMed]

71. Eriksen, K.W.; Sommer, V.H.; Woetmann, A.; Rasmussen, A.B.; Brender, C.; Svejgaard, A.; Skov, S.; Geisler, C.; Ødum, N. Bi-phasic effect of interferon (IFN)-alpha: IFN-alpha up-regulates interleukin-4 signaling in human T cells. *J. Biol. Chem.* 2004, 279, 169–176. [CrossRef]

72. Kim, T.K.; Maniatis, T. Regulation of Interleukin-gamma-Activated STAT1 by the Ubiquitin-Proteasome Pathway. *Science* 1996, 273, 1717–1719. [CrossRef]

73. Kurgonaitė, K.; Gandhi, H.; Kurth, T.; Pautot, S.; Schwille, P.; Weidemann, T.; Bökel, C. Essential role of endocytosis for Interleukin-4 receptor mediated JAK/STAT signalling. *J. Cell Sci.* 2015, 128, 3781–3795. [CrossRef] [PubMed]

74. Böhmer, F.-D.; Friedrich, K. Protein tyrosine phosphatases as wardens of STAT signaling. *JAK-STAT Rev.* 2014, 3, e28087. [CrossRef]

75. Niu, G.-J.; Xu, J.-D.; Yuan, W.-J.; Sun, J.-J.; Yang, M.-C.; He, Z.-H.; Zhao, X.-F.; Wang, J.-X. Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation. *Front. Immunol.* 2018, 9, 2392. [CrossRef] [PubMed]

76. Kershaw, N.; Murphy, J.; Liu, N.; Varghese, L.N.; Laktyushin, A.; Whitlock, E.L.; Lucet, I.S.; Nicola, N.A.; Babon, J.J. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. *Nat. Struct. Mol. Biol.* 2013, 20, 469–476. [CrossRef] [PubMed]

77. Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7, 454–465. [CrossRef]

78. Williams, J.J.L.; Munro, K.M.A.; Palmer, T.M. Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression. *Cells* 2014, 3, 546–562. [CrossRef] [PubMed]

79. Liu, N.P.D.; Laktyushin, A.; Lucet, I.S.; Murphy, J.M.; Yao, S.; Whitlock, E.; Callaghan, K.; Nicola, N.A.; Kershaw, N.J.; Babon, J.J. The molecular basis of JAK/STAT inhibition by SOCS1. *Nat. Commun.* 2018, 9, 1–14. [CrossRef] [PubMed]

80. Fasouli, E.S.; Katsantoni, E. JAK-STAT in Early Hematopoiesis and Leukemia. *Front. Cell Dev. Biol.* 2021, 9, 693633. [CrossRef] [PubMed]

81. Hammarén, H.M.; Virtanen, A.T.; Raivola, J.; Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in acute myeloid leukemia blasts. *Cytokine* 2019, 118, 48–63. [CrossRef]

82. Xia, Z.; Baer, M.R.; Block, A.W.; Baumann, H.; Wetzler, M. Expression of signal transducers and activators of transcription proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. *Blood* 1996, 88, 809–816. [CrossRef]

83. Liu, W.; Zou, F.; Yan, J.; Liu, Y.; Chen, C.; Zhang, K.; Zhao, X.; Chen, J. Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia. *Oncotargets Ther.* 2020, 13, 11165–11176. [CrossRef] [PubMed]

84. Shan, Y.; Gnanasambandan, K.; Ungureanu, D.; Kim, E.T.; Hammarén, H.; Yamashita, K.; Silvennoinen, O.; Shaw, D.E.; Hubbard, S.R.; Shaw, S.R.H. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. *Nat. Struct. Mol. Biol.* 2014, 21, 579–584. [CrossRef] [PubMed]

85. Venugopal, S.; Bar-Natan, M.; Mascarenhas, J.O. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. *Blood Rev.* 2020, 40, 100634. [CrossRef] [PubMed]

86. Metzeler, K.H.; Herold, T.; Rothenberg-Thurley, M.; Amler, S.; Sauerland, M.C.; Görlich, D.; Schneider, S.; Konstandin, N.P.; Dufour, A.; Bräundl, K.; et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood* 2016, 128, 668–696. [CrossRef]

87. Daver, N.; Schlenk, R.F.; Russell, N.H.; Levis, M.J. Targeting FLT3 mutations in AML: Review of current knowledge and evidence. *Leukemia* 2019, 33, 299–312. [CrossRef]

88. Choudhary, C.; Brandts, C.H.; Schwable, J.; Tickenbrock, L.; Sargin, B.; Uecker, A.; Böhmer, F.-D.; Berdel, W.E.; Müller-Tidow, C.; Serve, H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. *Blood* 2007, 110, 370–374. [CrossRef]

89. Ren, Z.; Aerts, J.L.; Pen, J.J.; Heirman, C.; Breekpot, K.; De Greve, J. Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer. *Oncogene* 2014, 34, 1650–1657. [CrossRef]

90. Rudorf, A.; Müller, T.A.; Klingeborg, C.; Kreutmann, S.; Poggio, T.; Gorantla, S.P.; Rückert, T.; Schmitt-Graeff, A.; Gengenbacher, A.; Paschka, P.; et al. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. *Blood* 2019, 134, 383–388. [CrossRef]

91. Dawson, M.A.; Gudgin, E.; Horton, S.J.; Giotopoulos, G.; Meduri, E.; Robson, S.; Cannizzaro, E.; Osaki, H.; Wiese, M.D.; Putwain, S.; et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. *Leukemia* 2013, 28, 311–320. [CrossRef]

92. Marcucci, G.; Metzeler, K.H.; Schwind, S.; Becker, H.; Maharry, K.; Mrózek, K.; Radmacher, M.D.; Kohlschmidt, J.; Nicolet, D.; Whitman, S.P.; et al. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults with Primary Cytogenetically Normal Acute Myeloid Leukemia. *J. Clin. Oncol.* 2012, 30, 742–750. [CrossRef] [PubMed]
Biomedicines 2021, 9, 1051

141. Chen, W.C.; Yuan, J.S.; Xing, Y.; Mitchell, A.; Mbong, N.; Popescu, A.C.; McLeod, J.; Gerhard, G.; Kennedy, J.A.; Bogdanoski, G.; et al. An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Res. 2016, 76, 1214–1224. [CrossRef]

142. Mesa, R.A.; Kiladjian, J.-J.; Catalano, J.V.; Devos, T.; Egstad, M.; Hellmann, A.; McLornan, D.; Shimoda, K.; Winton, E.F.; Deng, W.; et al. SIMPLIFY-I: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis. J. Clin. Oncol. 2017, 35, 3844–3850. [CrossRef]

143. Patel, A.A.; Odenike, O. The Next Generation of JAK Inhibitors: An Update on Fedratinib, Momelotinib, and Pacritinib. Curr. Hematol. Malig. Rep. 2020, 15, 409–418. [CrossRef]

144. Liu, S.; Marneth, A.; Alexe, G.; Walker, S.R.; Gandler, H.I.; Ye, D.Q.; Labella, K.; Mathur, R.; Tioniolo, P.A.; Tillgren, M.; et al. The kinases IKKβ and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018, 2, 3428–3442. [CrossRef]

145. Azhar, M.; Kincaid, Z.; Kesarwani, M.; Latif, T.; Starczynowski, D.; Azam, M. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. bioXvn 2021. [CrossRef]

146. Betts, B.C.; Young, J.W. Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019. Crit. Care Explor. 2020, 2, e0138. [CrossRef]

147. Spiekermann, K.; Biethahn, S.; Wilde, S.; Hiddemann, W.; Alves, F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur. J. Haematol. 2001, 67, 63–71. [CrossRef] [PubMed]

148. Kayser, S.; Levis, M.J. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: Clinical implications and limitations. Leuk. Lymphoma 2014, 55, 243–255. [CrossRef]

149. Yoshikawa, H.; Matsubara, K.; Qian, G.-S.; Jackson, P.E.; Groopman, J.D.; Manning, J.E.; Harris, C.C.; Herman, J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hematopoietic carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28, 29–35. [CrossRef]

150. Koppikar, P.; Bhagwat, N.; Kilpivaara, O.; Manshouri, T.; Adli, M.; Hricik, T.; Liu, F.; Saunders, L.M.; Mullally, A.; Abdel-Wahab, O.; et al. Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nat. Cell Biol. 2012, 489, 155–159. [CrossRef] [PubMed]

151. DeArmond, D.; Brattain, M.G.; Jessup, J.M.; Kreisberg, J.; Malik, S.; Zhao, S.; Freeman, J.W. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003, 22, 7781–7795. [CrossRef]

152. Spiekermann, K.; Bagrintseva, K.; Schwab, R.; Schmieja, K.; Hiddemann, W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 2003, 9, 154.

153. Sumitomo Dainippon Pharma Oncology, Inc. A Study of BBi608 in Adult Patients with Advanced, Refractory Hematologic Malignancies. Available online: https://ClinicalTrials.gov/show/NCT02352558 (accessed on 24 June 2021).

154. Redell, M.S.; Ruiz, M.J.; Alonzo, T.A.; Gerbing, R.B.; Tweardy, D.J. Stat3 signaling in acute myeloid leukemia: Ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011, 117, 5701–5709. [CrossRef] [PubMed]

155. Bai, L.; Zhou, H.; Xu, R.; Zhao, Y.; Chinnaswamy, K.; McEachern, D.; Chen, J.; Yang, C.-Y.; Liu, Z.; Wang, M.; et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell 2019, 36, 498–511.e17. [CrossRef] [PubMed]

156. Hong, D.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; Zhou, T.; Schmidt, J.; Jo, M.; et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl. Med. 2015, 7, 314ra185. [CrossRef]

157. Reilley, M.J.; McCoon, P.; Cook, C.; Lyne, P.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial. J. Immunother. Cancer 2018, 6, 119. [CrossRef] [PubMed]

158. Hossain, D.M.S.; Santos, C.D.; Zhang, Q.; Kozlowska, A.; Liu, H.; Gao, C.; Moreira, D.; Swiderski, P.; Jozwiak, A.; Kline, J.; et al. In Vivo Targeting of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results in T Cell-Dependent Tumor Eradication. Blood 2013, 122, 4212. [CrossRef]

159. Zhang, Q.; Hossain, M.S.; Duttagupta, P.; Moreira, D.; Zhao, X.; Won, H.; Buettner, R.; Nechaev, S.; Majka, M.; Zhang, B.; et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 2016, 127, 1687–1700. [CrossRef] [PubMed]

160. Page, B.D.G.; Khoury, H.; Laister, R.C.; Fletcher, S.; Vellozo, M.; Manzoli, A.; Yue, P.; Turkson, J.; Minden, M.D.; Gunning, P.T. Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity. J. Med. Chem. 2012, 55, 1047–1055. [CrossRef]

161. Hankey, P.A. Regulation of hematopoietic cell development and function by Stat3. Front. Biosci. 2009, 14, 5273–5290. [CrossRef]

162. Hutchins, A.P.; Diez, D.; Miranda-Saavedra, D. The IL-10/STAT3-mediated anti-inflammatory response: Recent developments and future challenges. Brief. Funct. Genom. 2013, 12, 489–498. [CrossRef]

163. Bruserud, Ø.; Nepstad, I.; Hauge, M.; Hatfield, K.J.; Reikvam, H. STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia. Expert Rev. Hematol. 2014, 8, 29–41. [CrossRef] [PubMed]
164. Aoki, Y.; Feldman, G.M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. *Blood* 2003, 101, 1535–1542. [CrossRef]

165. Redell, M.S.; Ruiz, M.J.; Gerbing, R.B.; Alonzo, T.A.; Lange, B.J.; Tewardy, D.J.; Meshinchi, S. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: A Children’s Oncology Group report. *Blood* 2013, 121, 1083–1093. [CrossRef] [PubMed]

166. Koskela, H.L.; Eldfors, S.; Ellonen, P.; Van Adrichem, A.J.; Kuusanmäki, H.; Andersson, E.; Lagström, S.; Clemente, M.J.; Olson, T.; Jalkanen, S.E.; et al. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia. *N. Engl. J. Med.* 2012, 366, 1905–1913. [CrossRef]

167. Pilati, C.; Amessou, M.; BIhl, M.P.; Balabaud, C.; Van Nhieu, J.T.; Paradis, V.; Nault, J.C.; Izard, T.; Bioulac-Sage, P.; Couchy, G.; et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. *J. Exp. Med.* 2011, 208, 1359–1366. [CrossRef]

168. Genini, D.; Brambilla, L.; Laurini, E.; Merulla, J.; Civenni, G.; Pandit, S.; D’Antuono, R.; Perez, L.; Levy, D.E.; Pricl, S.; et al. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. *Proc. Natl. Acad. Sci. USA* 2017, 114, e4924–e4933. [CrossRef]

169. Brambilla, L.; Lahiri, T.; Cammer, M.; Levy, D.E. OPB-51602, a Direct Inhibitor of STAT3, Impairs Growth and Viability of Tumor Cells Through Inhibition of Respiratory Complex I. *SSRN Electron. J.* 2020. [CrossRef]

170. Ogura, M.; Uchida, T.; Terui, Y.; Hayakawa, F.; Kobayashi, Y.; Naoe, T.; Tobinai, K.; Munakata, W.; et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. *Cancer Sci.* 2015, 106, 896–901. [CrossRef] [PubMed]

171. Di, J.-X.; Zhang, H.-Y. C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma. *Anti-Cancer Drugs* 2019, 30, 846–853. [CrossRef] [PubMed]

172. Kong, R.; Sun, G.; Li, X.; Wu, L.; Li, L.; Li, Y.; Wang, F.; Xuan, P.; Yang, S.; Sun, B.; et al. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer. *Front. Oncol.* 2020, 10, 612. [CrossRef]

173. Hubbard, J.M.; Grothey, A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. *Drugs* 2017, 77, 1091–1103. [CrossRef] [PubMed]

174. Jonker, D.J.; Nott, L.; Yoshino, T.; Gill, S.; Shapiro, J.; Ohtsu, A.; Vickers, M.M.; Wei, A.C.; Gao, Y.; et al. Napabucasin versus placebo in refractory advanced colorectal cancer: A randomised phase 3 trial. *Lancet Gastroenterol. Hepatol.* 2018, 3, 263–270. [CrossRef]

175. Bi, S.; Chen, K.; Feng, L.; Fu, G.; Yang, Q.; Deng, M.; Zhao, H.; Li, Z.; Yu, L.; Fang, Z.; et al. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage. *Eur. J. Pharmacol.* 2019, 855, 252–261. [CrossRef]

176. Dale, B.; Cheng, M.; Park, K.-S.; Kaniskan, H.U.; Xiong, Y.; Jin, J. Advancing targeted protein degradation for cancer therapy. *Nat. Rev. Cancer* 2021, 1–17. [CrossRef]

177. Shastri, A.; Choudhary, G.; Teixeira, M.; Gordon-Mitchell, S.; Ramachandra, N.; Bernard, L.; Bhattacharyya, S.; Lopez, R.; Pradhan, K.; Giricz, O.; et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. *J. Clin. Investig.* 2018, 128, 5479–5488. [CrossRef] [PubMed]

178. Daver, N.; Cortes, J.; Kantarjian, H.; Ravandi, F. Acute myeloid leukemia: Advancing clinical trials and promising therapeutics. *Expert Rev. Hematol.* 2016, 9, 433–445. [CrossRef] [PubMed]

179. Novartis Pharmaceuticals Corporation. RYDAPT® (Midostaurin) Capsules, for Oral Use. 2017. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf (accessed on 24 June 2021).

180. Astellas Pharma US Inc., XOSPATA® (Gilteritinib) Tablets, for Oral Use. 2018. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf (accessed on 24 June 2021).